rnai consortium trc version 1 library (Broad Clinical Labs)
Broad Clinical Labs is a verified supplier 
Broad Clinical Labs manufactures this product 
96
Structured Review
Broad Clinical Labs
rnai consortium trc version 1 library
Rnai Consortium Trc Version 1 Library, supplied by Broad Clinical Labs, used in various techniques. Bioz Stars score: 96/100, based on 781 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rnai+consortium+trc+version+1+library/RNA+Sequencing/pm39374726-121-31-37
Average 96 stars, based on 781 article reviews
Rnai Consortium Trc Version 1 Library, supplied by Broad Clinical Labs, used in various techniques. Bioz Stars score: 96/100, based on 781 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rnai+consortium+trc+version+1+library/RNA+Sequencing/pm39374726-121-31-37
Average 96 stars, based on 781 article reviews
rnai consortium trc version 1 library - by Bioz Stars,
2026-10
96/100 stars
Images
Related Articles
shRNA:Article Title: VCAM-1 targeted nanocarriers of shRNA-Smad3 mitigate endothelial-to-mesenchymal transition triggered by high glucose concentrations and osteogenic factors in valvular endothelial cells. Article Snippet: Endothelial to mesenchymal transition (EndMT) of valvular endothelial cells (VEC) is a key process in the development and progression of calcific aortic valve disease (CAVD).. High expression of the Smad3 transcription factor is crucial in the transition process.. We hypothesize that silencing Smad3 could hinder EndMT and provide a novel treatment for CAVD. Sequencing:Article Title: VCAM-1 targeted nanocarriers of shRNA-Smad3 mitigate endothelial-to-mesenchymal transition triggered by high glucose concentrations and osteogenic factors in valvular endothelial cells. Article Snippet: Endothelial to mesenchymal transition (EndMT) of valvular endothelial cells (VEC) is a key process in the development and progression of calcific aortic valve disease (CAVD).. High expression of the Smad3 transcription factor is crucial in the transition process.. We hypothesize that silencing Smad3 could hinder EndMT and provide a novel treatment for CAVD. Plasmid Preparation:Article Title: VCAM-1 targeted nanocarriers of shRNA-Smad3 mitigate endothelial-to-mesenchymal transition triggered by high glucose concentrations and osteogenic factors in valvular endothelial cells. Article Snippet: Endothelial to mesenchymal transition (EndMT) of valvular endothelial cells (VEC) is a key process in the development and progression of calcific aortic valve disease (CAVD).. High expression of the Smad3 transcription factor is crucial in the transition process.. We hypothesize that silencing Smad3 could hinder EndMT and provide a novel treatment for CAVD. Clone Assay:Article Title: VCAM-1 targeted nanocarriers of shRNA-Smad3 mitigate endothelial-to-mesenchymal transition triggered by high glucose concentrations and osteogenic factors in valvular endothelial cells. Article Snippet: Endothelial to mesenchymal transition (EndMT) of valvular endothelial cells (VEC) is a key process in the development and progression of calcific aortic valve disease (CAVD).. High expression of the Smad3 transcription factor is crucial in the transition process.. We hypothesize that silencing Smad3 could hinder EndMT and provide a novel treatment for CAVD. |